share_log

EF Hutton Initiates Coverage On Lantern Pharma With Buy Rating, Announces Price Target of $11

EF Hutton Initiates Coverage On Lantern Pharma With Buy Rating, Announces Price Target of $11

EF Hutton以買入評級啓動對Lantern Pharma的報道,宣佈目標股價爲11美元
Benzinga Real-time News ·  2022/11/01 04:56

EF Hutton analyst Michael King initiates coverage on Lantern Pharma (NASDAQ:LTRN) with a Buy rating and announces Price Target of $11.

EF Hutton分析師邁克爾·金對燈籠製藥(納斯達克:LTRN)的報道給予買入評級,並宣佈目標價為11美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論